[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100280040":3},{"organization":4,"armGroups":7,"interventions":194,"overallOfficials":387,"centralContacts":391,"locations":399,"responsibleParty":826,"collaborators":828,"id":867,"slug":868,"hasResults":869,"nctId":870,"briefTitle":871,"officialTitle":872,"acronym":873,"eligibilityCriteria":874,"healthyVolunteers":869,"sex":875,"minAge":876,"maxAge":395,"enrollmentInfo":877,"targetDuration":395,"studyType":880,"phases":881,"briefSummary":883,"conditions":884,"keywords":889,"overallStatus":402,"whyStopped":395,"lastUpdateSubmitDate":897,"lastUpdatePostDateStruct":898,"startDateStruct":901,"completionDateStruct":903,"leadSponsor":905,"locationsCount":906},{"fullName":5,"class":6},"The Netherlands Cancer Institute","OTHER",[8,14,19,24,29,34,39,44,49,54,59,64,69,74,79,84,89,94,99,104,109,114,119,124,129,134,139,144,149,154,159,164,169,174,179,184,189],{"label":9,"type":10,"description":11,"interventionNames":12},"Panitumumab","EXPERIMENTAL","Panitumumab for patients with a molecular tumor profile that can potentially be targeted by Panitumumab.",[13],"Drug: Panitumumab",{"label":15,"type":10,"description":16,"interventionNames":17},"Olaparib","Olaparib for patients with a molecular tumor profile that can potentially be targeted by Olaparib.",[18],"Drug: Olaparib",{"label":20,"type":10,"description":21,"interventionNames":22},"Dabrafenib","Dabrafenib for patients with a molecular tumor profile that can potentially be targeted by Dabrafenib.",[23],"Drug: Dabrafenib",{"label":25,"type":10,"description":26,"interventionNames":27},"Nilotinib","Nilotinib for patients with a molecular tumor profile that can potentially be targeted by nilotinib.",[28],"Drug: Nilotinib",{"label":30,"type":10,"description":31,"interventionNames":32},"Trametinib","Trametinib for patients with a molecular tumor profile that can potentially be targeted by trametinib.",[33],"Drug: Trametinib",{"label":35,"type":10,"description":36,"interventionNames":37},"Erlotinib","Erlotinib for patients with a molecular tumor profile that can potentially be targeted by erlotinib.",[38],"Drug: Erlotinib",{"label":40,"type":10,"description":41,"interventionNames":42},"Trastuzumab & Pertuzumab (combination)","Trastuzumab and Pertuzumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab and Pertuzumab.",[43],"Drug: Trastuzumab and Pertuzumab (combination treatment)",{"label":45,"type":10,"description":46,"interventionNames":47},"Vemurafenib & Cobimetinib (combination)","Vemurafenib and Cobimetinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Vemurafenib and Cobimetinib.",[48],"Drug: Vemurafenib and Cobimetinib (combination treatment)",{"label":50,"type":10,"description":51,"interventionNames":52},"Vismodegib","Vismodegib for patients with a molecular tumor profile that can potentially be targeted by vismodegib.",[53],"Drug: Vismodegib",{"label":55,"type":10,"description":56,"interventionNames":57},"Regorafenib","Regorafenib for patients with a molecular tumor profile that can potentially be targeted by regorafenib.",[58],"Drug: Regorafenib",{"label":60,"type":10,"description":61,"interventionNames":62},"Nivolumab","Nivolumab for patients with a molecular tumor profile that can potentially be targeted by nivolumab.",[63],"Drug: Nivolumab",{"label":65,"type":10,"description":66,"interventionNames":67},"Afatinib","Afatinib for patients with a molecular tumor profile that can potentially be targeted by Afatinib.",[68],"Drug: Afatinib",{"label":70,"type":10,"description":71,"interventionNames":72},"Dabrafenib & trametinib (combination)","Dabrafenib and trametinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Dabrafenib and trametinib.",[73],"Drug: Dabrafenib and trametinib",{"label":75,"type":10,"description":76,"interventionNames":77},"Ribociclib","Ribociclib for patients with a molecular tumor profile that can potentially be targeted by Ribociclib.",[78],"Drug: Ribociclib",{"label":80,"type":10,"description":81,"interventionNames":82},"Lenvatinib","Lenvatinib for patients with a molecular tumor profile that can potentially be targeted by Lenvatinib.",[83],"Drug: Lenvatinib",{"label":85,"type":10,"description":86,"interventionNames":87},"Pembrolizumab","Pembrolizumab for patients with a molecular tumor profile that can potentially be targeted by Pembrolizumab.",[88],"Drug: Pembrolizumab",{"label":90,"type":10,"description":91,"interventionNames":92},"Durvalumab","Durvalumab for patients with a molecular tumor profile that can potentially be targeted by Durvalumab.",[93],"Drug: Durvalumab",{"label":95,"type":10,"description":96,"interventionNames":97},"Rucaparib","Rucaparib for patients with a molecular tumor profile that can potentially be targeted by Rucaparib.",[98],"Drug: Rucaparib",{"label":100,"type":10,"description":101,"interventionNames":102},"Axitinib","Axitinib for patients with a molecular tumor profile that can potentially be targeted by Axitinib.",[103],"Drug: Axitinib",{"label":105,"type":10,"description":106,"interventionNames":107},"Palbociclib","Palbociclib for patients with a molecular tumor profile that can potentially be targeted by Palbociclib.",[108],"Drug: Palbociclib",{"label":110,"type":10,"description":111,"interventionNames":112},"Crizotinib","Crizotinib for patients with a molecular tumor profile that can potentially be targeted by Crizotinib.",[113],"Drug: Crizotinib",{"label":115,"type":10,"description":116,"interventionNames":117},"Sunitinib","Sunitinib for patients with a molecular tumor profile that can potentially be targeted by Sunitinib.",[118],"Drug: Sunitinib",{"label":120,"type":10,"description":121,"interventionNames":122},"Cabozantinib","Cabozantinib for patients with a molecular tumor profile that can potentially be targeted by Cabozantinib.",[123],"Drug: Cabozantinib",{"label":125,"type":10,"description":126,"interventionNames":127},"Abemaciclib","Abemaciclib for patients with a molecular tumor profile that can potentially be targeted by Abemaciclib.",[128],"Drug: Abemaciclib",{"label":130,"type":10,"description":131,"interventionNames":132},"Alectinib","Alectinib for patients with a molecular tumor profile that can potentially be targeted by Alectinib.",[133],"Drug: Alectinib",{"label":135,"type":10,"description":136,"interventionNames":137},"Atezolizumab\u002Fbevacizumab","Atezolizumab and bevacizumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Atezolizumab and bevacizumab.",[138],"Drug: Atezolizumab and Bevacizumab",{"label":140,"type":10,"description":141,"interventionNames":142},"Ipilimumab\u002Fnivolumab","Ipilimumab and nivolumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Ipilimumab and nivolumab.",[143],"Drug: Ipilimumab and nivolumab",{"label":145,"type":10,"description":146,"interventionNames":147},"Entrectinib","Entrectinib for patients with a molecular tumor profile that can potentially be targeted by entrectinib.",[148],"Drug: Entrectinib",{"label":150,"type":10,"description":151,"interventionNames":152},"Talazoparib","Talazoparib for patients with a molecular tumor profile that can potentially be targeted by talazoparib.",[153],"Drug: Talazoparib",{"label":155,"type":10,"description":156,"interventionNames":157},"dacomitinib","Dacomitinib for patients with a molecular tumor profile that can potentially be targeted by dacomitinib.",[158],"Drug: Dacomitinib",{"label":160,"type":10,"description":161,"interventionNames":162},"Lorlatinib","Lorlatinib for patients with a molecular tumor profile that can potentially be targeted by lorlatinib.",[163],"Drug: Lorlatinib",{"label":165,"type":10,"description":166,"interventionNames":167},"Erdafitinib","Erdafitinib for patients with a molecular tumor profile that can potentially be targeted by erdafitinib.",[168],"Drug: Erdafitinib",{"label":170,"type":10,"description":171,"interventionNames":172},"Alpelisib","Alpelisib for patients with a molecular tumor profile that can potentially be targeted by alpelisib.",[173],"Drug: Alpelisib",{"label":175,"type":10,"description":176,"interventionNames":177},"Niraparib","Niraparib for patients with a molecular tumor profile that can potentially be targeted by niraparib.",[178],"Drug: Niraparib",{"label":180,"type":10,"description":181,"interventionNames":182},"Pemigatinib","Pemigatinib for patients with a molecular tumor profile that can potentially be targeted by pemigatinib.",[183],"Drug: Pemigatinib",{"label":185,"type":10,"description":186,"interventionNames":187},"Selpercatinib","Selpercatinib for patients with a molecular tumor profile that can potentially be targeted by selpercatinib.",[188],"Drug: Selpercatinib",{"label":190,"type":10,"description":191,"interventionNames":192},"Tepotinib","Tepotinib for patients with a molecular tumor profile that can potentially be targeted by tepotinib.",[193],"Drug: Tepotinib",[195,201,206,211,216,221,226,232,238,243,248,253,258,264,269,274,279,284,289,294,299,304,309,314,319,324,330,336,341,346,352,357,362,367,372,377,382],{"type":196,"name":9,"description":197,"armGroupLabels":198,"otherNames":199},"DRUG","Panitumumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of panitumumab might be expected based on their molecular tumor profile.",[9],[200],"Vectibix",{"type":196,"name":15,"description":202,"armGroupLabels":203,"otherNames":204},"Olaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of olaparib might be expected based on their molecular tumor profile.",[15],[205],"Lynparza",{"type":196,"name":20,"description":207,"armGroupLabels":208,"otherNames":209},"Dabrafenib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dabrafenib might be expected based on their molecular tumor profile.",[20],[210],"Tafinlar",{"type":196,"name":25,"description":212,"armGroupLabels":213,"otherNames":214},"Nilotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nilotinib might be expected based on their molecular tumor profile.",[25],[215],"Tasigna",{"type":196,"name":30,"description":217,"armGroupLabels":218,"otherNames":219},"Trametinib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trametinib might be expected based on their molecular tumor profile.",[30],[220],"Mekinist",{"type":196,"name":35,"description":222,"armGroupLabels":223,"otherNames":224},"Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erlotinib might be expected based on their molecular tumor profile.",[35],[225],"Tarceva",{"type":196,"name":227,"description":228,"armGroupLabels":229,"otherNames":230},"Trastuzumab and Pertuzumab (combination treatment)","Trastuzumab and Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trastuzumab + pertuzumab might be expected based on their molecular tumor profile.",[40],[231],"Herceptin + Perjeta",{"type":196,"name":233,"description":234,"armGroupLabels":235,"otherNames":236},"Vemurafenib and Cobimetinib (combination treatment)","Vemurafenib + Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib + Cobimetinib might be expected based on their molecular tumor profile.",[45],[237],"Zelboraf + Cotellic",{"type":196,"name":50,"description":239,"armGroupLabels":240,"otherNames":241},"Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.",[50],[242],"Erivedge",{"type":196,"name":55,"description":244,"armGroupLabels":245,"otherNames":246},"Regorafenib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.",[55],[247],"Stivarga",{"type":196,"name":60,"description":249,"armGroupLabels":250,"otherNames":251},"Nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nivolumab might be expected based on their molecular tumor profile.",[60],[252],"Opdivo",{"type":196,"name":65,"description":254,"armGroupLabels":255,"otherNames":256},"Afatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Afatinib might be expected based on their molecular tumor profile.",[65],[257],"Giotrif",{"type":196,"name":259,"description":260,"armGroupLabels":261,"otherNames":262},"Dabrafenib and trametinib","Dabrafenib + trametinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Dabrafenib + Trametinib might be expected based on their molecular tumor profile.",[70],[263],"Tafinlar and Mekinist",{"type":196,"name":75,"description":265,"armGroupLabels":266,"otherNames":267},"Ribociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Ribociclib might be expected based on their molecular tumor profile.",[75],[268],"Kisqali",{"type":196,"name":80,"description":270,"armGroupLabels":271,"otherNames":272},"Lenvatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Lenvatinib might be expected based on their molecular tumor profile.",[80],[273],"Lenvima",{"type":196,"name":85,"description":275,"armGroupLabels":276,"otherNames":277},"Pembrolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Pembrolizumab might be expected based on their molecular tumor profile.",[85],[278],"Keytruda",{"type":196,"name":90,"description":280,"armGroupLabels":281,"otherNames":282},"Durvalumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Durvalumab might be expected based on their molecular tumor profile.",[90],[283],"MEDI4736",{"type":196,"name":95,"description":285,"armGroupLabels":286,"otherNames":287},"Rucaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Rucaparib might be expected based on their molecular tumor profile.",[95],[288],"Rubraca",{"type":196,"name":100,"description":290,"armGroupLabels":291,"otherNames":292},"Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.",[100],[293],"Inlyta",{"type":196,"name":105,"description":295,"armGroupLabels":296,"otherNames":297},"Palbociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Palbociclib might be expected based on their molecular tumor profile.",[105],[298],"Ibrance",{"type":196,"name":110,"description":300,"armGroupLabels":301,"otherNames":302},"Crizotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Crizotinib might be expected based on their molecular tumor profile.",[110],[303],"Xalkori",{"type":196,"name":115,"description":305,"armGroupLabels":306,"otherNames":307},"Sunitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Sunitinib might be expected based on their molecular tumor profile.",[115],[308],"Sutent",{"type":196,"name":120,"description":310,"armGroupLabels":311,"otherNames":312},"Cabozantinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Cabozantinib might be expected based on their molecular tumor profile.",[120],[313],"Cabometyx",{"type":196,"name":125,"description":315,"armGroupLabels":316,"otherNames":317},"Abemaciclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Abemaciclib might be expected based on their molecular tumor profile.",[125],[318],"Verzenios",{"type":196,"name":130,"description":320,"armGroupLabels":321,"otherNames":322},"Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.",[130],[323],"Alecensa",{"type":196,"name":325,"description":326,"armGroupLabels":327,"otherNames":328},"Atezolizumab and Bevacizumab","Atezolizumab + Bevacizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab + Bevacizumab might be expected based on their molecular tumor profile.",[135],[329],"Tecentriq and Avastin",{"type":196,"name":331,"description":332,"armGroupLabels":333,"otherNames":334},"Ipilimumab and nivolumab","Ipilimumab+nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of ipilimimab + nivolumab might be expected based on their molecular tumor profile.",[140],[335],"Yervoy and Opdivo",{"type":196,"name":145,"description":337,"armGroupLabels":338,"otherNames":339},"Entrectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of entrectinib might be expected based on their molecular tumor profile.",[145],[340],"Rozlytrek",{"type":196,"name":150,"description":342,"armGroupLabels":343,"otherNames":344},"Talazoparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of talazoparib might be expected based on their molecular tumor profile.",[150],[345],"Talzenna",{"type":196,"name":347,"description":348,"armGroupLabels":349,"otherNames":350},"Dacomitinib","Dacomitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dacomitinib might be expected based on their molecular tumor profile.",[155],[351],"Vizimpro",{"type":196,"name":160,"description":353,"armGroupLabels":354,"otherNames":355},"Lorlatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of lorlatinib might be expected based on their molecular tumor profile.",[160],[356],"Lorviqua",{"type":196,"name":165,"description":358,"armGroupLabels":359,"otherNames":360},"Erdafitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erdafitinib might be expected based on their molecular tumor profile.",[165],[361],"Balversa",{"type":196,"name":170,"description":363,"armGroupLabels":364,"otherNames":365},"Alpelisib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of alpelisib might be expected based on their molecular tumor profile.",[170],[366],"Piqray",{"type":196,"name":175,"description":368,"armGroupLabels":369,"otherNames":370},"Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of niraparib might be expected based on their molecular tumor profile.",[175],[371],"Zejula",{"type":196,"name":180,"description":373,"armGroupLabels":374,"otherNames":375},"Pemigatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of pemigatinib might be expected based on their molecular tumor profile.",[180],[376],"Pemazyre",{"type":196,"name":185,"description":378,"armGroupLabels":379,"otherNames":380},"Selpercatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of selpercatinib might be expected based on their molecular tumor profile.",[185],[381],"Retsevmo",{"type":196,"name":190,"description":383,"armGroupLabels":384,"otherNames":385},"Tepotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of tepotinib might be expected based on their molecular tumor profile.",[190],[386],"Tepmetko",[388],{"name":389,"affiliation":5,"role":390},"E.E. Voest, prof.","PRINCIPAL_INVESTIGATOR",[392,397],{"name":389,"role":393,"phone":394,"phoneExt":395,"email":396},"CONTACT","0031205129111",null,"DRUP@nki.nl",{"name":398,"role":393,"phone":394,"phoneExt":395,"email":396},"K. Verkerk, MD",[400,416,428,441,454,464,471,480,492,504,516,528,540,552,564,577,590,602,614,623,635,648,660,672,684,696,708,721,733,746,755,767,776,789,802,814],{"facility":401,"status":402,"city":403,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":406,"geoPoint":411,"contacts":412},"Noordwest ziekenhuisgroep Alkmaar (NWZ)","RECRUITING","Alkmaar","Netherlands","NL",{"type":407,"coordinates":408},"Point",[409,410],4.74861,52.63167,{"lat":410,"lon":409},[413,415],{"name":414,"role":393,"phone":395,"phoneExt":395,"email":395},"M.P. Hendriks, MD, PhD",{"name":414,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":417,"status":402,"city":418,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":419,"geoPoint":423,"contacts":424},"Ziekenhuisgroep Twente","Almelo",{"type":407,"coordinates":420},[421,422],6.6625,52.35667,{"lat":422,"lon":421},[425,427],{"name":426,"role":393,"phone":395,"phoneExt":395,"email":395},"E. Siemerink",{"name":426,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":429,"status":402,"city":430,"state":395,"zip":431,"country":404,"countryCode":405,"cosmosGeoPoint":432,"geoPoint":436,"contacts":437},"Meander medisch centrum","Amersfoort","3818 ES",{"type":407,"coordinates":433},[434,435],5.3875,52.155,{"lat":435,"lon":434},[438,440],{"name":439,"role":393,"phone":395,"phoneExt":395,"email":395},"G.A. Cirkel, MD",{"name":439,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":442,"status":402,"city":443,"state":395,"zip":444,"country":404,"countryCode":405,"cosmosGeoPoint":445,"geoPoint":449,"contacts":450},"Netherlands Cancer Institute","Amsterdam","1066CX",{"type":407,"coordinates":446},[447,448],4.88969,52.37403,{"lat":448,"lon":447},[451,452],{"name":389,"role":393,"phone":394,"phoneExt":395,"email":396},{"name":453,"role":393,"phone":394,"phoneExt":395,"email":396},"K Verkerk, MD",{"facility":455,"status":402,"city":443,"state":395,"zip":456,"country":404,"countryCode":405,"cosmosGeoPoint":457,"geoPoint":459,"contacts":460},"Amsterdam UMC, locatie VUmc","1081 HV",{"type":407,"coordinates":458},[447,448],{"lat":448,"lon":447},[461,463],{"name":462,"role":393,"phone":395,"phoneExt":395,"email":395},"M Labots",{"name":462,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":465,"status":466,"city":443,"state":395,"zip":467,"country":404,"countryCode":405,"cosmosGeoPoint":468,"geoPoint":470,"contacts":395},"Amsterdam UMC, locatie AMC","ACTIVE_NOT_RECRUITING","1105AZ",{"type":407,"coordinates":469},[447,448],{"lat":448,"lon":447},{"facility":472,"status":402,"city":443,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":473,"geoPoint":475,"contacts":476},"Onze Lieve Vrouwe Gasthuis (OLVG)",{"type":407,"coordinates":474},[447,448],{"lat":448,"lon":447},[477,479],{"name":478,"role":393,"phone":395,"phoneExt":395,"email":395},"E.D. Kerver",{"name":478,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":481,"status":402,"city":482,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":483,"geoPoint":487,"contacts":488},"Gelre ziekenhuizen","Apeldoorn",{"type":407,"coordinates":484},[485,486],5.96944,52.21,{"lat":486,"lon":485},[489,491],{"name":490,"role":393,"phone":395,"phoneExt":395,"email":395},"S.C.S. Tromp",{"name":490,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":493,"status":402,"city":494,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":495,"geoPoint":499,"contacts":500},"Rijnstate ziekenhuis","Arnhem",{"type":407,"coordinates":496},[497,498],5.91111,51.98,{"lat":498,"lon":497},[501,503],{"name":502,"role":393,"phone":395,"phoneExt":395,"email":395},"T. van Voorthuizen",{"name":502,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":505,"status":402,"city":506,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":507,"geoPoint":511,"contacts":512},"Amphia Ziekenhuis","Breda",{"type":407,"coordinates":508},[509,510],4.77596,51.58656,{"lat":510,"lon":509},[513,515],{"name":514,"role":393,"phone":395,"phoneExt":395,"email":395},"H. Westgeest, MD, PhD",{"name":514,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":517,"status":402,"city":518,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":519,"geoPoint":523,"contacts":524},"Reiner de Graaf Gasthuis","Delft",{"type":407,"coordinates":520},[521,522],4.35556,52.00667,{"lat":522,"lon":521},[525,527],{"name":526,"role":393,"phone":395,"phoneExt":395,"email":395},"A. Vulink",{"name":526,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":529,"status":402,"city":530,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":531,"geoPoint":535,"contacts":536},"Deventer ziekenhuis","Deventer",{"type":407,"coordinates":532},[533,534],6.16389,52.255,{"lat":534,"lon":533},[537,539],{"name":538,"role":393,"phone":395,"phoneExt":395,"email":395},"A. Imholz",{"name":538,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":541,"status":402,"city":542,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":543,"geoPoint":547,"contacts":548},"Nij Smellinghe Ziekenhuis","Drachten",{"type":407,"coordinates":544},[545,546],6.0989,53.11254,{"lat":546,"lon":545},[549,551],{"name":550,"role":393,"phone":395,"phoneExt":395,"email":395},"S. Hovenga",{"name":550,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":553,"status":402,"city":554,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":555,"geoPoint":559,"contacts":560},"Ziekenhuis Gelderse Vallei","Ede",{"type":407,"coordinates":556},[557,558],5.65833,52.03333,{"lat":558,"lon":557},[561,563],{"name":562,"role":393,"phone":395,"phoneExt":395,"email":395},"P. de Mol",{"name":562,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":565,"status":402,"city":566,"state":395,"zip":567,"country":404,"countryCode":405,"cosmosGeoPoint":568,"geoPoint":572,"contacts":573},"Maxima Medisch Centrum","Eindhoven","5631 BM",{"type":407,"coordinates":569},[570,571],5.47778,51.44083,{"lat":571,"lon":570},[574,576],{"name":575,"role":393,"phone":395,"phoneExt":395,"email":395},"G Vreugdenhil, MD, PhD",{"name":575,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":578,"status":402,"city":579,"state":395,"zip":580,"country":404,"countryCode":405,"cosmosGeoPoint":581,"geoPoint":585,"contacts":586},"Zuyderland medisch centrum","Geleen","6162 BG",{"type":407,"coordinates":582},[583,584],5.82917,50.97417,{"lat":584,"lon":583},[587,589],{"name":588,"role":393,"phone":395,"phoneExt":395,"email":395},"F.L.G. Erdkamp, MD",{"name":588,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":591,"status":402,"city":592,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":593,"geoPoint":597,"contacts":598},"Rivas zorggroep","Gorinchem",{"type":407,"coordinates":594},[595,596],4.97243,51.83652,{"lat":596,"lon":595},[599,601],{"name":600,"role":393,"phone":395,"phoneExt":395,"email":395},"M.A. Davidis",{"name":600,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":603,"status":402,"city":604,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":605,"geoPoint":609,"contacts":610},"Martini ziekenhuis","Groningen",{"type":407,"coordinates":606},[607,608],6.56667,53.21917,{"lat":608,"lon":607},[611,613],{"name":612,"role":393,"phone":395,"phoneExt":395,"email":395},"J. van Rooijen",{"name":612,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":615,"status":402,"city":604,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":616,"geoPoint":618,"contacts":619},"University Medical Center Groningen",{"type":407,"coordinates":617},[607,608],{"lat":608,"lon":607},[620,622],{"name":621,"role":393,"phone":395,"phoneExt":395,"email":395},"D.J.A. de Groot, MD, PhD",{"name":621,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":624,"status":402,"city":625,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":626,"geoPoint":630,"contacts":631},"Spaarne gasthuis","Haarlem",{"type":407,"coordinates":627},[628,629],4.63683,52.38084,{"lat":629,"lon":628},[632,634],{"name":633,"role":393,"phone":395,"phoneExt":395,"email":395},"G.J. de Klerk",{"name":633,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":636,"status":637,"city":638,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":639,"geoPoint":643,"contacts":644},"Tergooi MC","NOT_YET_RECRUITING","Hilversum",{"type":407,"coordinates":640},[641,642],5.17639,52.22333,{"lat":642,"lon":641},[645,647],{"name":646,"role":393,"phone":395,"phoneExt":395,"email":395},"H.P. van den Berg",{"name":646,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":649,"status":402,"city":650,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":651,"geoPoint":655,"contacts":656},"Treant zorggroep","Hoogeveen",{"type":407,"coordinates":652},[653,654],6.47639,52.7225,{"lat":654,"lon":653},[657,659],{"name":658,"role":393,"phone":395,"phoneExt":395,"email":395},"C. Oldenhuis",{"name":658,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":661,"status":402,"city":662,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":663,"geoPoint":667,"contacts":668},"Medisch Centrum Leeuwaarden","Leeuwarden",{"type":407,"coordinates":664},[665,666],5.80973,53.20271,{"lat":666,"lon":665},[669,671],{"name":670,"role":393,"phone":395,"phoneExt":395,"email":395},"H. de Graaf",{"name":670,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":673,"status":402,"city":674,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":675,"geoPoint":679,"contacts":680},"Leiden University Medical Center","Leiden",{"type":407,"coordinates":676},[677,678],4.49306,52.15833,{"lat":678,"lon":677},[681,683],{"name":682,"role":393,"phone":395,"phoneExt":395,"email":395},"A.J. Gelderblom, MD, PhD",{"name":682,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":685,"status":402,"city":686,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":687,"geoPoint":691,"contacts":692},"Maastricht University Medical Center","Maastricht",{"type":407,"coordinates":688},[689,690],5.68889,50.84833,{"lat":690,"lon":689},[693,695],{"name":694,"role":393,"phone":395,"phoneExt":395,"email":395},"A. Hoeben, MD, PhD",{"name":694,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":697,"status":402,"city":698,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":699,"geoPoint":703,"contacts":704},"St. Antonius ziekenhuis","Nieuwegein",{"type":407,"coordinates":700},[701,702],5.08056,52.02917,{"lat":702,"lon":701},[705,707],{"name":706,"role":393,"phone":395,"phoneExt":395,"email":395},"M. Los",{"name":706,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":709,"status":402,"city":710,"state":395,"zip":711,"country":404,"countryCode":405,"cosmosGeoPoint":712,"geoPoint":716,"contacts":717},"Radboud umc","Nijmegen","6225GA",{"type":407,"coordinates":713},[714,715],5.85278,51.8425,{"lat":715,"lon":714},[718,720],{"name":719,"role":393,"phone":395,"phoneExt":395,"email":395},"C.M.L. van Herpen, MD, PhD",{"name":719,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":722,"status":402,"city":723,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":724,"geoPoint":728,"contacts":729},"Bravis ziekenhuis","Roosendaal",{"type":407,"coordinates":725},[726,727],4.46528,51.53083,{"lat":727,"lon":726},[730,732],{"name":731,"role":393,"phone":395,"phoneExt":395,"email":395},"S. Boudewijns",{"name":731,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":734,"status":402,"city":735,"state":395,"zip":736,"country":404,"countryCode":405,"cosmosGeoPoint":737,"geoPoint":741,"contacts":742},"St. Fransicus Gasthuis","Rotterdam","3045 PM",{"type":407,"coordinates":738},[739,740],4.47917,51.9225,{"lat":740,"lon":739},[743,745],{"name":744,"role":393,"phone":395,"phoneExt":395,"email":395},"A P Hamberg, MD",{"name":744,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":747,"status":402,"city":735,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":748,"geoPoint":750,"contacts":751},"Erasmus MC",{"type":407,"coordinates":749},[739,740],{"lat":740,"lon":739},[752,754],{"name":753,"role":393,"phone":395,"phoneExt":395,"email":395},"M.J.A. de Jonge, MD, PhD",{"name":753,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":756,"status":402,"city":757,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":758,"geoPoint":762,"contacts":763},"Haaglanden medisch centrum","The Hague",{"type":407,"coordinates":759},[760,761],4.29861,52.07667,{"lat":761,"lon":760},[764,766],{"name":765,"role":393,"phone":395,"phoneExt":395,"email":395},"F. Jeurissen",{"name":765,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":768,"status":402,"city":757,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":769,"geoPoint":771,"contacts":772},"Haga ziekenhuis",{"type":407,"coordinates":770},[760,761],{"lat":761,"lon":760},[773,775],{"name":774,"role":393,"phone":395,"phoneExt":395,"email":395},"D. Hautsma",{"name":774,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":777,"status":402,"city":778,"state":395,"zip":779,"country":404,"countryCode":405,"cosmosGeoPoint":780,"geoPoint":784,"contacts":785},"Elisabeth-TweeSteden Ziekenhuis","Tilburg","5022 GC",{"type":407,"coordinates":781},[782,783],5.0913,51.55551,{"lat":783,"lon":782},[786,788],{"name":787,"role":393,"phone":395,"phoneExt":395,"email":395},"L.V. Beerepoot, MD, PhD",{"name":787,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":790,"status":402,"city":791,"state":395,"zip":792,"country":404,"countryCode":405,"cosmosGeoPoint":793,"geoPoint":797,"contacts":798},"University Medical Center Utrecht","Utrecht","3584CX",{"type":407,"coordinates":794},[795,796],5.12222,52.09083,{"lat":796,"lon":795},[799,801],{"name":800,"role":393,"phone":395,"phoneExt":395,"email":395},"L.A. Devriese, MD, PhD",{"name":800,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":803,"status":402,"city":804,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":805,"geoPoint":809,"contacts":810},"VieCuri medisch centrum","Venlo",{"type":407,"coordinates":806},[807,808],6.16806,51.37,{"lat":808,"lon":807},[811,813],{"name":812,"role":393,"phone":395,"phoneExt":395,"email":395},"Y. van der Wouw",{"name":812,"role":390,"phone":395,"phoneExt":395,"email":395},{"facility":815,"status":402,"city":816,"state":395,"zip":395,"country":404,"countryCode":405,"cosmosGeoPoint":817,"geoPoint":821,"contacts":822},"Isala klinieken","Zwolle",{"type":407,"coordinates":818},[819,820],6.09444,52.5125,{"lat":820,"lon":819},[823,825],{"name":824,"role":393,"phone":395,"phoneExt":395,"email":395},"J.W.B. de Groot",{"name":824,"role":390,"phone":395,"phoneExt":395,"email":395},{"type":827,"investigatorFullName":395,"investigatorTitle":395,"investigatorAffiliation":395,"oldNameTitle":395,"oldOrganization":395},"SPONSOR",[829,832,834,836,838,840,842,844,846,848,850,852,855,857,859,861,863,865],{"name":830,"class":831},"Amgen","INDUSTRY",{"name":833,"class":831},"AstraZeneca",{"name":835,"class":831},"Bayer",{"name":837,"class":831},"Bristol-Myers Squibb",{"name":839,"class":831},"Novartis",{"name":841,"class":831},"Roche Pharma AG",{"name":843,"class":831},"Merck Sharp & Dohme LLC",{"name":845,"class":831},"Boehringer Ingelheim",{"name":847,"class":831},"Ipsen",{"name":849,"class":831},"Eisai Inc.",{"name":851,"class":831},"Pfizer",{"name":853,"class":854},"Clovis Oncology - Pharma and","UNKNOWN",{"name":856,"class":831},"Eli Lilly and Company",{"name":858,"class":831},"Janssen, LP",{"name":860,"class":831},"GlaxoSmithKline",{"name":862,"class":831},"Incyte Corporation",{"name":864,"class":6},"Dutch Cancer Society",{"name":866,"class":854},"Stelvio for Life","100280040","phase-2-the-drug-rediscovery-protocol-drup-trial-100280040",false,"NCT02925234","The Drug Rediscovery Protocol (DRUP Trial)","A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile","DRUP","Inclusion Criteria:\n\n1. Adult (age \\>18 years) patient with a histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphomawith symptomatic disease progression or progression according to RECIST-criteria after standard anti-cancer treatment or for whom no such treatment is available or indicated.\n\n   \\* For patients with a primary brain tumor: Histologically confirmed recurrent or de novo primary brain tumor, with unequivocal progression after prior therapy, at least 3 months after radiotherapy (either first line chemo-radiotherapy or re-irradiation), and with stable or decreasing dosage of steroids for at least 7 days prior to the baseline MRI scan.\n2. ECOG performance status 0-2\n3. Patients must have acceptable organ function as defined below. However, specific inclusion\u002Fexclusion criteria specified in the drug-specific study manual will take precedence:\n\n   1. Absolute neutrophil count ≥ 1.5 x 109\u002Fl\n   2. Hemoglobin \\> 5.6 mmol\u002Fl\n   3. Platelets \\> 75 x 109\u002Fl\n   4. Total bilirubin \\\u003C 2 x ULN\n   5. AST (SGOT) and ALT (SGPT) \\\u003C 2.5 x institutional ULN (or \\\u003C 5 x ULN in patients with known hepatic metastases)\n   6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL\u002Fmin\u002F1.73 m2\n4. Patients must have objectively measurable disease (by physical or radiographic examination, according to RECIST v1.1 for patients with solid tumors, or according to IMWG, Lugano, RANO or GCIG criteria, resp., for patients with multiple myeloma, non-Hodgkin lymphoma, glioblastoma or ovarian cancer in case of CA125-based evaluation (please refer to appendices for further details).\n5. Results must be available from a tumor genomic or protein expression test. Eligible tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS) or immunohistochemistry (IHC). The test may have been performed on the primary tumor or a metastatic deposit, in a diagnostic laboratory or within the context of another CPCT study, and must reveal a potentially actionable variant as defined in Section 5. The test results (full pathology or molecular diagnostics report) must be uploaded in the eCRF.\n6. Patients must have a tumor profile for which treatment with one of the FDA and \u002F or EMA approved (or under revision for approval) targeted anti-cancer drugs included in this study has potential clinical benefit based on preclinical data or clinical information (see section 5).\n7. new (obtained ≤2 months before inclusion, and without any type of anti-cancer therapy within those ≤2 months) fresh frozen tumor biopsy specimen for extensive biomarker testing is mandatory before the start of treatment with a targeted agent included in the protocol. Alternatively, fresh frozen tumor tissue acquired in the context of a standard care procedure may be used, provided that no systemic anti-cancer treatment was given between the procedure and start of study treatment within DRUP.\n\n   The following exceptions are made:\n\n   a. An exception is made for patients with a primary brain tumor, only if the mandatory DRUP pre-treatment biopsy for biomarker analysis cannot safely be obtained:\n   1. The fresh frozen tumor biopsy sample may be replaced by fresh frozen tumor tissue, obtained earlier from recurrent disease, as part of standard of care surgical procedure (i.e., performed at progression)\n   2. If no fresh frozen tumor tissue is available for NGS, and the risk of obtaining a new tumor biopsy is considered too high, no biopsy will be required. In this case, the study coordinators must be informed in advance, and there will be no reimbursement for the biopsy procedure.\n\n   b. In case WGS is performed on tumor tissue outside the context of a clinical trial before inclusion, and without any type of anti-cancer therapy between the collection of tissue and inclusion in DRUP, this can replace the DRUP pre-treatment biopsy, provided that the patient gives consent to use his\u002Fher WGS data for biomarker analysis in DRUP.\n\n   c. An exception is made for patients that underwent an allogeneic hematopoietic stem cell transplantation prior to study enrollment, since this will prevent a correct WGS analysis due to a mismatch between the biopsy specimen and the required blood sample.\n8. Ability to understand and the willingness to sign a written informed consent document.\n9. For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.\n10. Because of the risks of drug treatment to the developing foetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Male patients should avoid impregnating a female partner. Male patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse.\n\nExclusion Criteria:\n\n1. Ongoing toxicity \\> grade 2, other than alopecia.\n2. Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement). Required wash out period prior to starting study treatment is at least two weeks. An exception is made for:\n\n   * Patients suffering from CRPC are allowed to continue androgen deprivation therapy.\n   * Medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates). These medications must have been started ≥ 1 week prior to enrollment on this study.\n3. Patient is pregnant or nursing.\n4. Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to registration. All patients with previously treated brain metastases must be stable for at least 1 month after completion of treatment and off steroid treatment prior to study enrollment.\n\n   \\* Additional exclusion criteria specific for glioblastoma patients:\n   1. Patients who require anti-convulsant therapy must be taking non-enzyme inducing antiepileptic drugs (non-EIAED). EIAED are prohibited. Patients previously on EIAED must be switched to non-EIAED at least 2 weeks prior to randomization.\n   2. No radiotherapy within the three months prior to the diagnosis of progression.\n   3. No radiotherapy with a dose over 65 Gy, stereotactic radiosurgery or brachytherapy unless the recurrence is histologically proven.\n5. Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.\n6. Patients with known left ventricular ejection fraction (LVEF) \\\u003C 40% are not eligible\n7. Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment are not eligible\n8. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness\u002Fsocial situations.\n\nFor each drug included in this protocol, specific inclusion and exclusion criteria (based on the Package Insert or manufacturers recommendations) may also apply. These can be found in the supplemental information about each agent included in the drug-specific study manuals. Drug-specific inclusion and exclusion criteria will take precedence over the inclusion\u002Fexclusion criteria listed above.","ALL","18 Years",{"count":878,"type":879},1550,"ESTIMATED","INTERVENTIONAL",[882],"PHASE2","This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer drugs\\* prescribed for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic or protein expression test. The study also aims to simplify patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing on tumor biopsies for biomarker analyses. Eligible patients have an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma for which standard treatment options are no longer available and acceptable performance status and organ function. A genomic or protein expression test must have been performed on the tumor and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Results from the molecular profiling test will be used to determine an appropriate drug(s) from among those available in the protocol. The choice of drug will be supported by a list of potential profiles, a molecular tumor board, a knowledge library and by study coordinators for review and approval of the match. The protocol-specified treatment will be administered to the patient once any drug-specific eligibility criteria are confirmed and a fresh pre-treatment biopsy is performed for future genetic studies. All patients who receive treatment with a drug available in the protocol will be followed for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment. In addition, treatment related toxicity will be evaluated.",[885,886,887,888],"Cancer","Tumors","Neoplasm","Neoplasia",[890,891,892,893,894,895,896],"Molecular tumor profile","Multidisciplinary tumor board","Antitumor drugs","Molecular Targeted Therapy","Drug Repositioning","Off-Label Use","Sequence Analysis, DNA","2024-01-22",{"date":899,"type":900},"2024-01-24","ACTUAL",{"date":902,"type":900},"2016-08",{"date":904,"type":879},"2027-12",{"name":5,"class":6},36]